Comparative Pharmacology
Head-to-head clinical analysis: FOSFOMYCIN TROMETHAMINE versus SATRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOSFOMYCIN TROMETHAMINE versus SATRIC.
FOSFOMYCIN TROMETHAMINE vs SATRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fosfomycin inhibits bacterial cell wall synthesis by inactivating the enzyme UDP-N-acetylglucosamine enolpyruvyl transferase (MurA), which catalyzes the first step of peptidoglycan biosynthesis.
SATRIC is a combination of sulfathiazole, sulfacetamide, and sulfabenzamide, which are sulfonamide antibiotics. They competitively inhibit dihydropteroate synthase, blocking folate synthesis in susceptible bacteria.
3 g orally once as a single dose for uncomplicated urinary tract infection.
No standard dosing information available for SATRIC.
None Documented
None Documented
Terminal elimination half-life is 5.7 hours (range 3-8 hours) in patients with normal renal function; approximately 50 hours in end-stage renal disease (CrCl <10 mL/min).
3-5 hours in healthy adults; prolonged to 6-8 hours in renal impairment (CrCl < 30 mL/min)
Primarily excreted unchanged in urine via glomerular filtration (approximately 90% of absorbed dose within 24-48 hours); small amount (approximately 10%) excreted in feces via biliary elimination.
Renal: 70% unchanged; fecal: 20%; biliary: 10%
Category A/B
Category C
Antibiotic
Antiprotozoal, Antibiotic